Everything below concerns angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-28. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
== History == In 1995, a study by the National Institute of Neurological Disorders and Stroke showed the effectiveness of administering intravenous alteplase to treat ischemic stroke. This sparked a medical paradigm shift as it redesigned stroke treatment in the emergency department to allow for timely assessment and therapy for ischemic stroke patients.
=== Regulatory approach === Unlike the European Union, which enacted the comprehensive, risk-based EU AI Act (Regulation (EU) 2024/1689), the UK has maintained a "pro-innovation" and sector-specific regulatory approach. Rather than creating a single AI regulator or primary legislation, the UK relies on existing sector-specific regulator, including the Competition and Markets Authority (CMA), the Information Commissioner's Office (ICO), the Financial Conduct Authority (FCA), and Ofcom, to apply cross-cutting principles of safety, transparency, fairness, accountability, and contestability to AI systems within their respective domains.
== Life cycle == Adult brown recluse spiders often live about one to two years. Each female produces several egg sacs over a period of two to three months, from May to July, with approximately 50 eggs in each sac. The eggs hatch in about one month. The spiderlings take about one year to grow to adulthood. The brown recluse spider is resilient and can tolerate up to six months of extreme drought and scarcity or absence of food. On one occasion, a brown recluse survived in controlled captivity for over five seasons without any food at all. As part of the haplogynae, brown recluses do not balloon, which limits their ability to widely disperse geographically. The brown recluse will, though not habitually, cannibalize another if food becomes scarce; especially during its typical mating season from June to September or when an unreceptive female encounters an aggressive male.
Slurry ice can boost by up to 200% the cooling efficiency of existing cooling or freezing brine systems without any major changes to the system (i.e. heat exchanger, pipes, valves), and reduce the amount of energy consumption used for pumping.
Sources: en.wikipedia.org
The enzyme characterised from Escherichia coli combines adenosine triphosphate and nicotinate mononucleotide to give deamido-NAD, a precursor to the coenzyme, nicotinamide adenine dinucleotide (NAD). Pyrophosphate (PPi) is a byproduct. In organisms which use this biosynthetic pathway to NAD, the final step is an amidation reaction. This enzyme belongs to the family of transferases, specifically those transferring phosphorus-containing nucleotide groups (nucleotidyltransferases). The systematic name of this enzyme class is ATP:nicotinate-ribonucleotide adenylyltransferase. Other names in common use include deamido-NAD+ pyrophosphorylase, nicotinate mononucleotide adenylyltransferase, deamidonicotinamide adenine dinucleotide pyrophosphorylase, NaMN-ATase, and nicotinic acid mononucleotide adenylyltransferase.
Collectivistic cultures are more likely to use norms and the social appraisals of others in evaluating their subjective well-being, whereas those [individualistic] societies are more likely to heavily weight the internal [frame of reference] arising from one's own happiness.
== Distribution and habitat == The worldwide northern temperate distribution of the genus distinguishes it from the remaining largely tropical Violaceae genera, restricted to either Old World or New World species, while in the tropics the distribution is primarily in high mountainous areas. Centres of diversity occur mainly in the northern hemisphere, in mountainous regions of eastern Asia, Melanesia, and southern Europe, but also occur in the Andes and the southern Patagonian cone of South America. One of the highest species concentrations is in the former USSR. Australia is home to a number of Viola species, including Viola hederacea, Viola betonicifolia and Viola banksii, first collected by Joseph Banks and Daniel Solander on the Cook voyage to Botany Bay.
=== Glycogenolysis === Glycogenolysis refers to the breakdown of glycogen. In the liver, muscles, and the kidney, this process occurs to provide glucose when necessary. A single glucose molecule is cleaved from a branch of glycogen, and is transformed into glucose-1-phosphate during this process. This molecule can then be converted to glucose-6-phosphate, an intermediate in the glycolysis pathway. Glucose-6-phosphate can then progress through glycolysis. Glycolysis only requires the input of one molecule of ATP when the glucose originates in glycogen. Alternatively, glucose-6-phosphate can be converted back into glucose in the liver and the kidneys, allowing it to raise blood glucose levels if necessary. Glucagon in the liver stimulates glycogenolysis when the blood glucose is lowered, known as hypoglycemia. The glycogen in the liver can function as a backup source of glucose between meals. Liver glycogen mainly serves the central nervous system. Adrenaline stimulates the breakdown of glycogen in the skeletal muscle during exercise. In the muscles, glycogen ensures a rapidly accessible energy source for movement.
== Works cited == Dill, Marshall (1954). "The Christian Trade Unions During the Last Years of Imperial Germany and the First Months of the Weimar Republic". Review of Social Economy. 12 (2). Taylor & Francis, Ltd.: 89–109. doi:10.1080/00346765400000024. ISSN 0034-6764. JSTOR 29767502. Retrieved 25 March 2024. Grünthal, Günther (1968). Reichsschulgesetz und Zentrumspartei in der Weimarer Republik. Beiträge zur Geschichte des Parlamentarismus und der politischen Parteien (in German). Droste. ISBN 978-3-7700-5056-7. Retrieved 27 November 2024. Grünthal, Günther (1979). ""Zusammenschluß" oder "Evangelisches Zentrum"? Ein Beitrag zur Geschichte der Deutschen Zentrumspartei in der Weimarer Republik". In Pöls, Werner (ed.). Staat und Gesellschaft im politischen Wandel. Beiträge zur Geschichte der modernen Welt (in German). Stuttgart: Klett Cotta. pp. 301–330. ISBN 9783129119006. Mitchell, Maria (2012). "Confessional Conflict in German History". The Origins of Christian Democracy: Politics and Confession in Modern Germany. Social History, Popular Culture, And Politics In Germany. University of Michigan Press. ISBN 978-0-472-02854-2. Retrieved 27 November 2024. Schmidgall, Markus (2012). Die Revolution 1918/19 in Baden. Karlsruhe Institute of Technology. ISBN 9783866447271.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.